30 results about "L929 cell" patented technology

Oligonucleotide sequence i.e. adaptor including DNA sequence and RNA sequence can combine with TNF alpha in specificity so as to restrain damaging effect on L929 cells from TNF alpha. The invented adaptor can be utilized to test TNF alpha and cure disease caused by raised level of TNF alpha. Comparing with current antagon of TNF alpha, the invented adaptor possesses advantages of high specificity, high affinity, fast reaching target tissue and quick plasma clearance etc. The oligonucleotide sequence possesses affinity and specificity of monoclonal antibody as well as permeability and pharmacokinetics characters of small molecule polypeptide. The invention is also related to derivation sequence and modified sequence of oligonucleotide, as well as its usage, preparation and diagnosis in curing disease relevant to TNF alpha.

The invention discloses a building method for autovaccine in-vivo induced by aiming at human TNF(Tumor Necrosis Factor)-alpha molecule. With a step-by-step cloning method, a fusion gene of hTNF-TT830-844, hTNF-HEL46-61 and hTNF-PADRE is built; point mutation (T439-A,C440-G) is introduced into a natural human TNF gene to optimize a mRNA (Ribonucleic Acid) secondary structure; the fusion gene is cloned into a pET22b prokaryotic expression vector, and efficient expression is achieved in the bacterial strain of escherichia coli; three T accessory cell epitope peptides are introduced between the epitope peptide structure domains of hTNF by the computer-aided analysis and is fused with the hTNF-alpha to overcome the immunological tolerance of an organism for the autologous protein, and therefore the organism generates high-level humoral immune response; the generated high-level hTNF-alpha neutralizing polyclone antibody can neutralize killing activity of the hTNF-alpha on L929 cells in vitro; the hTNF-PADRE has the strongest immunogenicity; the high-level antibody can be induced under the condition of using no immunological adjuvant; and the vaccine has favorable protection and curing action on mouse models suffering from rheumatoid arthritis induced by the II-type collagen, cachexia and the like induced by LPS (lipopolysaccharide).

Provided is high-strength high-plasticity biodegradable Zn-Mn-Li zinc alloy. The alloy comprises 0.01-0.8% of Mn and 0.005-0.4% of Li, wherein Mn is the main alloying element, Li is the minor alloyingelement, and the content of Mn is not lower than the content of Li in the alloy; at least one of Na, K, Ca, Sr, Ti, Mg, Fe, Cu and Ag is selected, wherein the content of Na and the content of K are both not higher than 0.1%, and the total content of Na, K and Li is not higher than 0.4%; the content of Ca, the content of Sr, the content of Ti and the content of Mg are all not higher than 0.2%, andthe total content of Ca, Sr, Ti and Mg is not higher than 0.2%; the content of Fe is not higher than 0.05%; the adding amount of Cu and the adding amount of Ag are not higher than 0.4%, and the totalcontent of Cu and Ag is not higher than 0.4%; and the total content of alloy elements added into the Zn-Mn-Li zinc alloy is not higher than 1.8%, and the balance Zn. The yield strength of the zinc alloy is 250-450 MPa, the tensile strength of the zinc alloy is 350-600 MPa, and the ductility is 20-60%; the degrading rate in simulated body fluid is not higher than 0.15 mm / year; the cytotoxicity tothe L929 cell is at the level 0 or level 1, and good cytocompatibility is presented. The zinc alloy is used for a degradable bracket or other medical implants.

The present invention relates to an isoxazole derivative, the compound of formula (I)herein after referred to as GIT27-NO, which is the NO-donating structurally modified form of (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, herein after referred to as VGX-1027. Treatment of three tumor cell lines, rat astrocytoma C6, mouse fibrosarcoma L929, and mouse melanoma B16 cells with GIT27-NO resulted in a significant reduction of cell respiration and of number of viable cells, while VGX-1027 was completely ineffective. Hemoglobin, which act as NO-scavenger, restored cell viability, thus indicating the NO-mediated tumoricidal effect of compound (I). GIT27-NO triggered apoptotic cell death in L929 cell cultures, while autophagic cell death is mainly responsible for the diminished viability of C6 and B16 cells. Moreover, GIT27-NO induced the production of reactive oxygen species which can be neutralized by antioxidant N-acetyl cysteine (NAC), indicating that reactive oxygen species (ROS) are at least partly involved in the reduction of cell viability. The anti-tumor activity of GIT27-NO is mediated through activation of MAP kinases (ERK1 / 2, p38 and JNK) in cell-specific manner. The role of MAP kinases was further confirmed by specific inhibitors of these molecules, PD98059, SB202190, and SP600125. Finally, in vivo treatment with GIT27-NO significantly reduced tumor growth in syngeneic C57BL / 6 mice implanted with B16 melanoma.

The invention discloses a biodegradable Zn-Na-series zinc alloy, and belongs to the field of medical implant materials. The biodegradable Zn-Na-series zinc alloy comprises 0.01-0.97% of Na, one or more of 27 elements which are harmless or beneficial to a human body, and the balance Zn, wherein in order to lower the cost and obtain excellent comprehensive performance, the total amount of the addedvarious alloy elements is optimally controlled to be no more than 2.0%. A preparation processing process of the zinc alloy comprises the steps of continuous casting, hot extrusion and rolling; or continuous casting, hot extrusion, solidification heat treatment and drawing; or continuous casting, uniform heat treatment, hot extrusion and rolling. According to the biodegradable Zn-Na-series zinc alloy, the yield strength is 100-500 MPa, the tensile strength is 150-700 MPa, and the elongation is 1.5-100%; the degradation rate in simulated body fluid is no more than 0.8 mm / year; and the cytotoxicity to L929 cells and human mesenchymal stem cells is at the zero stage or the one stage, good biocompatibility is shown, and the biodegradable Zn-Na-series zinc alloy can be used for various medical implants.

The application provides a feeder-free hybridoma liquid culture medium, wherein the hybridoma liquid culture medium contains: a, 20%-30% of the total volume of cultured L929 cells; b, accounting for 20%-30% of the total volume; 20%-30% of the total volume of culture medium for culturing C6 / 36 cells; c, 8%-20% of the total volume of fetal bovine serum. Compared with the prior art, this application omits the cumbersome process of preparing feeder cells, making the synthetic hybridoma cells easier to observe and able to grow and reproduce normally.

The present invention discloses anti-human TNF-alpha monoclonal antibodies which have light chain amino acid sequence (SEQ ID NO: 3) and heavy chain amino acid sequence (SEQ ID NO: 4 or SEQ ID NO: 6). The anti-human TNF-alpha monoclonal antibodies have complete human antibody sequences to ensure low immunogenicity. The manufacturing methods and uses of the antibodies are also provided.

The invention discloses a new natural product catathelasma imperiale sing polysaccharide CIS-A and an application thereof. The catathelasma imperiale sing polysaccharide CIS-A is heteropolysaccharide composed of two monosaccharides, namely alpha-D-glucose and beta-L-galactose, in a ratio of 3:2, the average molecular weight is about 50486Da, the alpha-D-glucose connected by 1,3- and the alpha-D-glucose connected by 1,2,3- are main chains, and a side chain is the beta-L-galactose connected by two 2,3-. The catathelasma imperiale sing polysaccharide CIS-A laetiporus sulphureus polysacharride has obvious immunoregulatory activity, heteropolysaccharide CIS-A can have an obvious inhibiting effect on L929 cells cultured in vitro, and the survival rate of the cells is 68.9% when the concentration of CIS-A is 5 mu g / mL; and growth of S180 tumor is inhibited in vivo, and the inhibition ratio reaches up to 64.4%.

The invention relates to a non-serum animal cell culture used fetus cattle serum displace agent, which is formed by recombination human insulin growth factor-1:0.1g-0.5g / l, recombination human platelet sourced growth factor-B:0.1g-0.6g / l, recombination human alkali desmocyte growth factor: 0.05-0.4g / l, cattle transferring: 1g-5g / l, cattle serum protein (V component): 2g-15g / l, and mercaptoethanol 0.3-0.5mol / l.

The invention provides a compound having anticancer activity, which is obtained by cooperation of Norabieta cantharidin and platinum (IV) and modification of a piperazine derivative. The compound is characterized in that a Norabieta cantharidin piperazine derivative ligand is introduced, thereby cytotoxicity of a platinum (IV) compound is reduced, and high antineoplastic activity is provided. The result of the cytotoxicity experiments shows that the provided platinum (IV) compound has less destruction to normal mice fibroblast L929, but has good killing effect to cancer cells such as human breast cancer MCF-7 cell, human cervical carcinoma HeLa cell and human lung adenocarcinoma A549 cell, so that the compound having anticancer activity is capable of reducing the system toxicity and having equal anticancer activity with cisplatin. The compound having anticancer activity has good killing effect by aiming at cisplatin resistance human lung adenocarcinoma A549 / DDP cell. Therefore, the toxicity is reduced, the cisplatin resistance can be reversed, and anticancer effect of the platinum medicines can be increased.